Skip to main content
SpringerLink
Log in

Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Of a total study group of 99 patients 56 received intrapleural BCG in three different dosages (5 patients 16×106, 25 patients 32×106, and 26 patients 64×106 culturable particles) following resection treatment for lung cancer. This study group was compared with an historical control population, very closely matched with regard to age, sex, stage of disease, histology and type of operation.

Although the clinical condition of the patients selected for BCG treatment was above average, no survival benefit ensued from the intrapleural BCG. On the contrary, disease-free survival in BCG receivers with stage I and II squamous cell carcinoma was shortened significantly at 2 years follow-up due to the earlier appearance of local recurrences, with the same tendency still present after 5 years. This observation suggests an enhancement of tumour growth by the intrapleural BCG treatment. This alarming phenomenon could be a warning to clinicians when planning clinical immunotherapy trials to be aware of the potentially deleterious effects of such treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bakker W, Nijhuis-Heddes JMA, Wever AMJ, Brutel de la Rivière A, Van der Velde EA, Dijkman JH (1981) Postoperative intrapleural BCG in lung cancer: Lack of efficacy and possible enhancement of tumour growth. Thorax 36:870

    Google Scholar 

  2. Bakker W, Nijhuis-Heddes JMA, Brutel de la Rivière A, Dijkman JH (1982) Complications of postoperative intrapleural BCG in lung cancer. Ann Thorac Surg 33:267

    Google Scholar 

  3. Bast RC, Zbar B, Borsos T, Rapp HJ (1974) BCG and cancer I. N Engl J Med 290:1413

    Google Scholar 

  4. Bennett JA, McKneally MF (1982) Toxicity of high-dose intrapleural BCG (letter). Thorax 37:640

    Google Scholar 

  5. Bennett JA, Gruft H, McKneally MF, Zelterman D, Crispen RG (1983) Differences in biological activity among batches of lyophilized Tice Bacillus Calmette-Guérin and their association with clinical course in stage I lung cancer. Cancer Res 43:4183

    Google Scholar 

  6. Bhide SV, Maree GB, Sawai MM, Ranadive KJ (1978) Isoniazid tumorigenicity in mice under different experimental conditions. Int J Cancer 21:381

    Google Scholar 

  7. Brown CA, Brown IN, Sljivic VS (1980) Active suppression masks an underlying enhancement of antibody production in vitro by spleen cells from BCG-infected mice. Immunology 40:303

    Google Scholar 

  8. Cady B, Clifton EE (1967) Empyema and survival following surgery for bronchogenic carcinoma. J Thorac Cardiovasc Surg 53:102

    Google Scholar 

  9. Colmerauer ME, Koziol JA, Pilch YH (1980) Enhancement of metastasis development by BCG immunotherapy. J Surg Oncol 14:235

    Google Scholar 

  10. Glassroth JL, White MC, Snider DE (1977) An assessment of the possible association of isoniazid with human cancer deaths. Am Rev Respir Dis 116:1065

    Google Scholar 

  11. Goldstraw P (1980) Postpneumonectomy empyema: the cloud with a silver lining? J Thorac Cardiovasc Surg 79:851

    Google Scholar 

  12. Harmer MH (ed) (1978) TNM classification of malignant tumours. 3rd edition. UICC, Geneva

    Google Scholar 

  13. Jansen HM, The TH, Orie NGM (1980) Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax 35:781

    Google Scholar 

  14. Kaledin VI, Kurunov YN, Matienko NA, Nikolin VP (1978) Stimulation of tumour growth in mice by high doses of BCG. J Natl Cancer Inst 61:1393

    Google Scholar 

  15. Kato K, Yamamoto K, Kakinuma M, Ishihara C, Azuma I (1981) Suppression of BCG cell wall induced, delayed-type hypersensitivity by BCG pretreatment. I Induction of adherent suppressor cells by live BCG injection and their characterization. Immunology 42:259

    Google Scholar 

  16. Kenis Y (1980) Surgical adjuvant chemotherapy in non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 6:1075

    Google Scholar 

  17. Kjaer M (1982) Radiotherapy of squamous, adeno and large cell carcinoma of the lung. Cancer Treat Rev 9:1

    Google Scholar 

  18. Klimpel GR, Henney CS (1978) BCG-induced suppressor cells: I Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T cell generation in vitro. J Immunol 120:563

    Google Scholar 

  19. Kreyberg L, Liebow AA, Uehlinger EA (1967) Histological typing of lung tumours. WHO, Geneva

    Google Scholar 

  20. Law MR, Lam WK, Studdy PR, Pugsley WB, Hodson ME (1982) Complications of intrapleural BCG in the treatment of operable non-small cell bronchial carcinoma. Br J Dis Chest 76:151

    Google Scholar 

  21. Lowe J, Iles PB, Shore DF, Langman MJS, Baldwin RW (1980) Intrapleural BCG in operable lung cancer. Lancet I:11

    Google Scholar 

  22. Mathé G, Pouillart P, Lapeyraque F (1969) Active immunotherapy of L-1210 leukaemia applied after the graft of tumour cells. Br J Cancer 23:814

    Google Scholar 

  23. McKneally MF, Maver C, Kausel HW, Alley RD (1976) Regional immunotherapy with intrapleural BCG for lung cancer. J Thorac Cardiovasc Surg 72:333

    Google Scholar 

  24. McKneally MF, Maver CM, Kausel HW (1977) Intrapleural BCG immunostimulation in lung cancer. Lancet I:1003

    Google Scholar 

  25. McKneally MF, Maver C, Lininger L, Kausel HW, McIlduff JB, Older TM, Foster ED, Alley RD (1981) Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg 81:485

    Google Scholar 

  26. Minasian H, Lewis C, Evans S (1978) Influence of postoperative empyema on survival after pulmonary resection for bronchogenic carcinoma. Br Med J II 2:1329

    Google Scholar 

  27. Mountain CF (1976) The relationship of prognosis to morphology and the anatomic extent of disease: studies of a new clinical staging system. In: Israel L, Chahinian AP (eds) Lung cancer, natural history, prognosis, and therapy. Academic Press, New York, p 107

    Google Scholar 

  28. Mountain CF, Gail MH (1981) Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg 82:649

    Google Scholar 

  29. Ostenson RC, Lum LG (1984) In vitro differences in lymphocyte subpopulation reactivity in lung cancer patients: Purified Protein Derivative-specific suppressor T lymphocytes in patients who have received Bacillus Calmette-Guérin. Clin Immunol Immunopathol 30:233

    Google Scholar 

  30. Peterson A, Kirsh M, Sloan H (1981) Bronchogenic carcinoma and postoperative empyema: is survival really enhanced? Ann Thorac Surg 31:240

    Google Scholar 

  31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 35:1

    CAS  PubMed  Google Scholar 

  32. Piessens WF, Lachapelle FC, Legros N, Henson JC (1970) Facilitation of rat mammary tumour growth by BCG. Nature 228:1210

    Google Scholar 

  33. Roeslin N, Lang JM, Morand G, Wihlm JM, Witz JP (1982) Regional immunotherapy in resectable squamous cell lung carcinoma: analysis of a randomized study. Cancer Immunol Immunother 13:174

    Google Scholar 

  34. Rossing TH, Rossing RG (1982) Survival in lung cancer: an analysis of the effects of age, sex, resectability, and histopathologic type. Am Rev Respir Dis 126:771

    Google Scholar 

  35. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF (1972) Postoperative empyema improves survival in lung cancer. N Engl J Med 287:1013

    Google Scholar 

  36. Ruitenberg EJ, Sirks JL, Kreeftenberg JG, Sekhuis J, Tiesjema RH, van Hemert PA, Spits H, de Jong WH, Steerenberg PA, Kruizinga W, van Noorle Jansen LM, Smid P (1979) Some characteristics of BCG-RIV lot No. 057 to be used in a stage I melanoma trial organized by the European Organization for Research on Treatment of Cancer (EORTC): Report No. 134/79. National Institute of Public Health, Bilthoven, The Netherlands

    Google Scholar 

  37. Sacks H, Chalmers Th C, Smith H (1982) Randomized versus historical controls for clinical trials. Am J Med 72:233

    Google Scholar 

  38. Schrier DJ, Sternick JL, Allen EM, Moore VL (1981) Genetic basis of BCG induced suppression of delayed hypersensitivity. Nature 289:405

    Google Scholar 

  39. Selawry OS, Hansen HH (1982) Lung cancer. In: Holland JF, Frei E III (eds) Cancer medicine. Lea & Febiger, Philadelphia, p 1709

    Google Scholar 

  40. Takita H (1970) Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg 59:642

    Google Scholar 

  41. The Ludwig Lung Cancer Study Group (1981) Adverse reactions to intrapleural BCG. (Letter). N Engl J Med 305:167

    Google Scholar 

  42. The Ludwig Lung Cancer Study Group (1984) Lokale Immunstimulation bei operiertem nicht-kleinzelligem Bronchialkarzinom: Ergebnisse und Komplikationen. Dtsch Med Wochenschr 109:935

    Google Scholar 

  43. Witz JP, Roeslin N (1983) Postpneumonectomy empyema does not improve survival in bronchogenic carcinoma. Ann Thorac Surg 36:529

    Google Scholar 

  44. Zbar B, Bernstein ID, Bartlett GL, Hanna MG Jr, Rapp HJ (1972) Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injections of living Mycobacterium bovis. J Natl Cancer Inst 49:119

    Google Scholar 

  45. Zwilling BS, Davis GW (1980) Effect of Bacillus Calmette-Guérin on the development of primary lung cancer in Syrian gold hamsters. Cancer Res 40:3455

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Pulmonology, University Hospital, C3-P-11, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands

    W. Bakker & J. M. A. Nijhuis-Heddes

  2. Department of Medical Statistics, State University, Leiden, The Netherlands

    E. A. van der Velde

Authors
  1. W. Bakker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. A. Nijhuis-Heddes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. A. van der Velde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakker, W., Nijhuis-Heddes, J.M.A. & van der Velde, E.A. Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report. Cancer Immunol Immunother 22, 155–159 (1986). https://doi.org/10.1007/BF00199131

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199131

Keywords

Search

Navigation